Identification of thioredoxin-interacting protein 1 as a hypoxia-inducible factor 1α-induced gene in pancreatic cancer

Pancreas

Volumn 36, Issue 2, 2008, Pages 178-186

  Baker, Amanda F ^a,d   Koh, Mei Y ^b   Williams, Ryan R ^b   James, Brian ^b   Wang, Huamin ^b   Tate, Wendy R ^a   Gallegos, Alfred ^a   Von Hoff, Daniel D ^b,c   Han, Haiyong ^c   Powis, Garth ^b  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF ARIZONA   (United States)

Author keywords

HIF 1 ; Hypoxia; Pancreatic cancer; siRNA; Thioredoxin; TXNIP

Indexed keywords

CISPLATIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; OXALIPLATIN; SMALL INTERFERING RNA; THIOREDOXIN INTERACTING PROTEIN; ANTINEOPLASTIC AGENT; CARRIER PROTEIN; HIF1A PROTEIN, HUMAN; PLATINUM COMPLEX; THIOREDOXIN; TXN PROTEIN, HUMAN; TXNIP PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER THERAPY; CELL SELECTION; CELL SURVIVAL; CHEMOSENSITIVITY; CONTROLLED STUDY; CYTOTOXICITY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; GENE INDUCTION; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OPEN READING FRAME; PANCREAS CANCER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN INTERACTION; RNA ISOLATION; TISSUE MICROARRAY; TUMOR SUPPRESSOR GENE; WESTERN BLOTTING; CELL HYPOXIA; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MUTATION; PANCREAS CARCINOMA; PANCREAS TUMOR; PATHOLOGY; RNA INTERFERENCE; TUMOR CELL LINE; UPREGULATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, PANCREATIC DUCTAL; CARRIER PROTEINS; CELL HYPOXIA; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOHISTOCHEMISTRY; MUTATION; ORGANOPLATINUM COMPOUNDS; PANCREATIC NEOPLASMS; RNA INTERFERENCE; RNA, SMALL INTERFERING; THIOREDOXINS; TISSUE ARRAY ANALYSIS; TRANSFECTION; UP-REGULATION;

EID: 45549106739     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPA.0b013e31815929fe     Document Type: Article

References (41)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006;56:106-130.
2. Koong AC, Mehta VK, Le QT, et al. Pancreatic tumors show high levels of hypoxia. Int J Radiat Oncol Biol Phys. 2000;48:919-922.
3. Powis G, Montfort WR. Properties and biological activities of thioredoxins. Annu Rev Biophys Biomol Struct. 2001;30:421-455.
4. Welsh SJ, Bellamy WT, Briehl MM, et al. The redox protein thioredoxin-1 (Trx-1) increases hypoxia-inducible factor 1alpha protein expression: Trx-1 overexpression results in increased vascular endothelial growth factor production and enhanced tumor angiogenesis. Cancer Res. 2002;62:5089-5095.
5. Saitoh M, Nishitoh H, Fujii M, et al. Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1. EMBO J. 1998;17:2596-2606.
6. Meuillet EJ, Mahadevan D, Berggren M, et al. Thioredoxin-1 binds to the C2 domain of PTEN inhibiting PTEN's lipid phosphatase activity and membrane binding: a mechanism for the functional loss of PTEN's tumor suppressor activity. Arch Biochem Biophys. 2004;429:123-133.
7. Nakamura H, Bai J, Nishinaka Y, et al. Expression of thioredoxin and glutaredoxin, redox-regulating proteins, in pancreatic cancer. Cancer Detect Prev. 2000;24:53-60.
8. Raffel J, Bhattacharyya AK, Gallegos A, et al. Increased expression of thioredoxin-1 in human colorectal cancer is associated with decreased patient survival. J Lab Clin Med. 2003;142:46-51.
9. Goldberg SF, Miele ME, Hatta N, et al. Melanoma metastasis suppression by chromosome 6: evidence for a pathway regulated by CRSP3 and TXNIP. Cancer Res. 2003;63:432-440.
10. Han SH, Jeon JH, Ju HR, et al. VDUP1 upregulated by TGF-beta1 and 1,25-dihydroxyvitamin D3 inhibits tumor cell growth by blocking cell-cycle progression. Oncogene. 2003;22:4035-4046.
11. Jeon JH, Lee KN, Hwang CY, et al. Tumor suppressor VDUP1 increases p27(kip1) stability by inhibiting JAB1. Cancer Res. 2005;65: 4485-4489.
12. Yamanaka H, Maehira F, Oshiro M, et al. A possible interaction of thioredoxin with VDUP1 in HeLa cells detected in a yeast two-hybrid system. Biochem Biophys Res Commun. 2000;27:1796-800.
13. Junn E, Han SH, Im JY, et al. Vitamin D3 up-regulated protein 1 mediates oxidative stress via suppressing the thioredoxin function. J Immunol. 2000;164:6287-6295.
14. Jiang BH, Rue E, Wang GL, et al. Dimerization, DNA binding, and transactivation properties of hypoxia-inducible factor 1. J Biol Chem. 1996;271:17771-17778.
15. Semenza GL. HIF-1: mediator of physiological and pathophysiological responses to hypoxia. J Appl Physiol. 2000;88:1474-1480.
16. Welsh S, Williams R, Kirkpatrick L, et al. Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxiainducible factor-1alpha. Mol Cancer Ther. 2004;3:233-244.
17. Kitada T, Seki S, Sakaguchi H, et al. Clinicopathological significance of hypoxia-inducible factor-1alpha expression in human pancreatic carcinoma. Histopathology. 2003;43:550-555.
18. Chang Q, Qin R, Huang T, et al. Effect of antisense hypoxia-inducible factor 1alpha on progression, metastasis, and chemosensitivity of pancreatic cancer. Pancreas. 2006;32:297-305.
19. Chen J, Zhao S, Nakada K, et al. Dominant-negative hypoxia-inducible factor-1 alpha reduces tumorigenicity of pancreatic cancer cells through the suppression of glucose metabolism. Am J Pathol. 2003;162: 1283-1291.
20. Zhao Q, Du J, Gu H, et al. Effects of YC-1 on hypoxia-inducible factor 1-driven transcription activity, cell proliferative vitality, and apoptosis in hypoxic human pancreatic cancer cells. Pancreas. 2007; 34:242-247.
21. Belozerov VE, Van Meir EG. Hypoxia inducible factor-1: a novel target for cancer therapy. Anticancer Drugs. 2005;16:901-909.
22. Manalo DJ, Rowan A, Lavoie T, et al. Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1. Blood. 2005;105: 659-669.
23. Arner ES, Nakamura H, Sasada T, et al. Analysis of the inhibition of mammalian thioredoxin, thioredoxin reductase, and glutaredoxin by cis-diamminedichloroplatinum (II) and its major metabolite, the glutathione-platinum complex. Free Radic Biol Med. 2001;31: 1170-1178.
24. Witte AB, Anestal K, Jerremalm E, et al. Inhibition of thioredoxin reductase but not of glutathione reductase by the major classes of alkylating and platinum-containing anticancer compounds. Free Radic Biol Med. 2005;39:696-703.
25. Sasada T, Nakamura H, Ueda S, et al. Possible involvement of thioredoxin reductase as well as thioredoxin in cellular sensitivity to cis- diamminedichloroplatinum (II). Free Radic Biol Med. 1999;27: 504-514.
26. Koch S, Mayer F, Honecker F, et al. Efficacy of cytotoxic agents used in the treatment of testicular germ cell tumours under normoxic and hypoxic conditions in vitro. Br J of Cancer. 2003;89:2133-2139.
27. Song X, Liu X, Chi W, et al. Hypoxia-induced resistance to cisplatin and doxorubicin in non-small cell lung cancer is inhibited by silencing of HIF-1a gene. Cancer Chemother Pharamcol. 2006;58:776-784.
28. Kim KY, Shin SM, Kim JK, et al. Heat shock factor regulates VDUP1 gene expression. Biochem Biophys Res Commun. 2004;315: 369-375.
29. Le JS, Le MN, Cazes A, et al. Characterization of the expression of the hypoxia-induced genes neuritin, TXNIP and IGFBP3 in cancer. FEBS Lett. 2006;580:3395-3400.
30. Wang Z, Rong YP, Malone MH, et al. Thioredoxin-interacting protein (TXNIP) is a glucocorticoid-regulated primary response gene involved in mediating glucocorticoid-induced apoptosis. Oncogene. 2006;25: 1903-1913.
31. Minn AH, Hafele C, Shalev A. Thioredoxin-interacting protein is stimulated by glucose through a carbohydrate response element and induces beta-cell apoptosis. Endocrinology. 2005;146:2397-2405.
32. Sheth SS, Bodnar JS, Ghazalpour A, et al. Hepatocellular carcinoma in TXNIP-deficient mice. Oncogene. 2006;25:3528-3536.
33. Dutta KK, Nishinaka Y, Masutani H, et al. Two distinct mechanisms for loss of thioredoxin-binding protein-2 in oxidative stress-induced renal carcinogenesis. Lab Invest. 2005;85:798-807.
34. Yoshioka J, Schreiter ER, Lee RT. Role of thioredoxin in cell growth through interactions with signaling molecules. Antioxid Redox Signal. 2006;25:3528-3536.
35. Butler LM, Zhou X, Xu WS, et al. The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin. Proc Natl Acad Sci U S A. 2002;99:11700-11705.
36. Yoshida T, Kondo N, Oka S, et al. Thioredoxin-binding protein-2 (TBP-2): its potential roles in the aging process. Biofactors. 2006;27: 47-51.
37. Chung JW, Jeon JH, Yoon SR, et al. Vitamin D3 upregulated protein 1 (VDUP1) is a regulator for redox signaling and stress-mediated diseases. J Dermatol. 2006;33:662-669.
38. Oka S, Liu W, Masutani H, et al. Impaired fatty acid utilization in thioredoxin binding protein-2 (TBP-2)-deficient mice: a unique animal model of Reye syndrome. FASEB J. 2006;20:121-123.
39. Sheth SS, Castellani LW, Chari S, et al. Thioredoxin-interacting protein deficiency disrupts the fasting-feeding metabolic transition. J Lipid Res. 2005;46:123-134.
40. van Greevenbroek MM, Vermeulen VM, Feskens EJ, et al. Genetic variation in thioredoxin interacting protein (TXNIP) is associated with hypertriglyceridaemia and blood pressure in diabetes mellitus. Diabet Med. 2007;24:498-504.
41. Chen J, Couto FM, Minn AH, et al. Exenatide inhibits beta-cell apoptosis by decreasing thioredoxin-interacting protein. Biochem Biophys Res Commun. 2006;346:1067-1074.